![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LANCL2 |
Gene summary for LANCL2 |
![]() |
Gene information | Species | Human | Gene symbol | LANCL2 | Gene ID | 55915 |
Gene name | LanC like 2 | |
Gene Alias | GPR69B | |
Cytomap | 7p11.2 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | B3KTN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55915 | LANCL2 | LZE4T | Human | Esophagus | ESCC | 3.36e-03 | 1.28e-01 | 0.0811 |
55915 | LANCL2 | P2T-E | Human | Esophagus | ESCC | 2.10e-14 | 2.66e-01 | 0.1177 |
55915 | LANCL2 | P4T-E | Human | Esophagus | ESCC | 2.32e-08 | 2.01e-01 | 0.1323 |
55915 | LANCL2 | P8T-E | Human | Esophagus | ESCC | 2.81e-09 | 1.41e-01 | 0.0889 |
55915 | LANCL2 | P9T-E | Human | Esophagus | ESCC | 9.04e-07 | 1.68e-01 | 0.1131 |
55915 | LANCL2 | P10T-E | Human | Esophagus | ESCC | 7.48e-16 | 3.35e-01 | 0.116 |
55915 | LANCL2 | P12T-E | Human | Esophagus | ESCC | 1.66e-13 | 1.79e-01 | 0.1122 |
55915 | LANCL2 | P15T-E | Human | Esophagus | ESCC | 1.48e-20 | 4.23e-01 | 0.1149 |
55915 | LANCL2 | P16T-E | Human | Esophagus | ESCC | 1.02e-19 | 2.36e-01 | 0.1153 |
55915 | LANCL2 | P17T-E | Human | Esophagus | ESCC | 6.46e-04 | 1.56e-01 | 0.1278 |
55915 | LANCL2 | P20T-E | Human | Esophagus | ESCC | 1.79e-08 | 1.43e-01 | 0.1124 |
55915 | LANCL2 | P21T-E | Human | Esophagus | ESCC | 1.99e-06 | 1.04e-01 | 0.1617 |
55915 | LANCL2 | P22T-E | Human | Esophagus | ESCC | 3.19e-15 | 2.23e-01 | 0.1236 |
55915 | LANCL2 | P23T-E | Human | Esophagus | ESCC | 2.29e-29 | 7.62e-01 | 0.108 |
55915 | LANCL2 | P24T-E | Human | Esophagus | ESCC | 1.01e-06 | 8.85e-02 | 0.1287 |
55915 | LANCL2 | P26T-E | Human | Esophagus | ESCC | 1.27e-10 | 2.01e-01 | 0.1276 |
55915 | LANCL2 | P27T-E | Human | Esophagus | ESCC | 2.12e-19 | 2.57e-01 | 0.1055 |
55915 | LANCL2 | P28T-E | Human | Esophagus | ESCC | 2.77e-12 | 2.44e-01 | 0.1149 |
55915 | LANCL2 | P30T-E | Human | Esophagus | ESCC | 3.40e-05 | 2.59e-01 | 0.137 |
55915 | LANCL2 | P31T-E | Human | Esophagus | ESCC | 7.50e-09 | 2.06e-01 | 0.1251 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097305111 | Esophagus | ESCC | response to alcohol | 138/8552 | 253/18723 | 2.70e-03 | 1.14e-02 | 138 |
GO:000975516 | Esophagus | ESCC | hormone-mediated signaling pathway | 106/8552 | 190/18723 | 3.13e-03 | 1.30e-02 | 106 |
GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
GO:00973056 | Liver | NAFLD | response to alcohol | 42/1882 | 253/18723 | 7.91e-04 | 9.89e-03 | 42 |
GO:009730522 | Liver | HCC | response to alcohol | 138/7958 | 253/18723 | 6.91e-05 | 6.26e-04 | 138 |
GO:000975521 | Liver | HCC | hormone-mediated signaling pathway | 106/7958 | 190/18723 | 1.45e-04 | 1.17e-03 | 106 |
GO:009730519 | Oral cavity | OSCC | response to alcohol | 127/7305 | 253/18723 | 1.81e-04 | 1.24e-03 | 127 |
GO:0097305110 | Oral cavity | LP | response to alcohol | 80/4623 | 253/18723 | 7.24e-03 | 4.05e-02 | 80 |
GO:009730525 | Oral cavity | EOLP | response to alcohol | 53/2218 | 253/18723 | 2.31e-05 | 3.50e-04 | 53 |
GO:000975510 | Oral cavity | EOLP | hormone-mediated signaling pathway | 36/2218 | 190/18723 | 2.87e-03 | 1.70e-02 | 36 |
GO:00973063 | Oral cavity | EOLP | cellular response to alcohol | 20/2218 | 93/18723 | 5.62e-03 | 2.90e-02 | 20 |
GO:009730532 | Oral cavity | NEOLP | response to alcohol | 43/2005 | 253/18723 | 1.50e-03 | 1.06e-02 | 43 |
GO:000975515 | Oral cavity | NEOLP | hormone-mediated signaling pathway | 33/2005 | 190/18723 | 3.53e-03 | 2.07e-02 | 33 |
GO:009730612 | Oral cavity | NEOLP | cellular response to alcohol | 19/2005 | 93/18723 | 4.12e-03 | 2.33e-02 | 19 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LANCL2 | SNV | Missense_Mutation | c.970N>A | p.Ala324Thr | p.A324T | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LANCL2 | SNV | Missense_Mutation | novel | c.427N>A | p.Arg143Ser | p.R143S | Q9NS86 | protein_coding | tolerated(0.11) | possibly_damaging(0.841) | TCGA-D1-A16F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | novel | c.476N>T | p.Ala159Val | p.A159V | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | c.881N>G | p.Asp294Gly | p.D294G | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LANCL2 | SNV | Missense_Mutation | novel | c.151N>T | p.Arg51Cys | p.R51C | Q9NS86 | protein_coding | tolerated(0.12) | benign(0) | TCGA-EY-A1GE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | novel | c.901N>A | p.Phe301Ile | p.F301I | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | novel | c.1264G>A | p.Ala422Thr | p.A422T | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | novel | c.1231N>G | p.Pro411Ala | p.P411A | Q9NS86 | protein_coding | tolerated(0.15) | possibly_damaging(0.459) | TCGA-44-6777-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LANCL2 | SNV | Missense_Mutation | c.466N>T | p.Ala156Ser | p.A156S | Q9NS86 | protein_coding | deleterious(0.03) | possibly_damaging(0.566) | TCGA-44-7667-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LANCL2 | SNV | Missense_Mutation | novel | c.782N>T | p.Gly261Val | p.G261V | Q9NS86 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55915 | LANCL2 | NA | 384403642 | |||
55915 | LANCL2 | NA | 384403643 | |||
55915 | LANCL2 | NA | 384403644 |
Page: 1 |